Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Just For You 2 Small-Cap Biotechs That Could Reward Patient InvestorsWritten by Chris Markoch. Published 12/12/2025. 
Key Points - Small-cap biotech stocks like Mainz Biomed and NanoViricides offer high risk but the potential for outsized returns as their diagnostic and antiviral pipelines advance.
- Mainz Biomed’s ColoAlert test provides early commercial traction, but limited revenue and ongoing cash needs continue to pressure MYNZ stock.
- NanoViricides’ nanomedicine antiviral platform shows promising preclinical data, yet NNVC remains a speculative bet dependent on new funding and pipeline progress.
Speculative investors and patience rarely go hand in hand. Nevertheless, if you’re considering the small-cap biotech sector, patience is essential. Most of these companies are still in the clinical stage and do not have commercially available drugs or therapeutics. That also means negative earnings and little to no revenue. Success frequently hinges on the outcome of a single clinical-stage drug or therapeutic. A former billion-dollar hedge fund manager just made an unexpected move — releasing a free, over-the-shoulder demo of a strategy he's used for years.
In the brief presentation, he explains how focusing on one ticker at a time helped him stay consistent across different market cycles. Viewers also get access to a heavily discounted subscription and see the stock he's watching now. Watch the free demo here Even if a product advances through trials, profitability may still be years away. Only after reaching that milestone do companies typically attract analyst coverage and the institutional investment that often follows. But getting in on one of these medical stocks before a breakthrough can produce outsized returns. A single successful program can produce 3x, 5x, or even 10x gains. Many other names will never pan out, so investors interested in penny stocks often spread capital across multiple biotechs. If this is a numbers game, diversification can be an effective strategy. With that in mind, here are two small-cap biotech stocks that carry substantial risk but also the potential for outsized returns. Mainz Biomed: Early Cancer Detection With High Upside Potential Mainz Biomed AG (NASDAQ: MYNZ) is a German molecular diagnostics company focused on epigenetics-based tests for early cancer detection. Unlike many penny biotechs, Mainz Biomed has a commercially available product: ColoAlert—the first DNA-based screening tool for colorectal cancer in Europe. On Dec. 2, Mainz Biomed announced that ColoAlert was added to the portfolio of DoctorBox, a leading digital health company in Germany. With more than 60,000 new colorectal cancer cases annually in Germany, the addressable market is meaningful. Mainz Biomed is also developing a non-invasive blood-based screening test for early detection of pancreatic cancer and reported positive topline results from a feasibility study in October. Commercial approval for that program, however, is still years away. Risks are substantial. ColoAlert is not yet available in the United States, and despite early sales in Europe and plans to expand into South America, current revenue remains minimal. That limited revenue partly explains why the company included “Going Concern” language in its Sept. 26 SEC filing. Since then, Mainz Biomed filed a $150 million mixed-shelf offering to raise capital. For now, that financing helps keep the MYNZ share price above $1 and avoids a delisting notice. The company must generate meaningful revenue to shift its financial picture. If it succeeds, even a small stake could deliver a sizable return, but investors should be prepared for volatility and dilution risk. NanoViricides: High-Risk Antiviral Play With Breakthrough Potential NanoViricides Inc. (NYSE: NNVC) is a micro-cap biotech pursuing a potentially disruptive approach to antiviral therapy, but it carries the financial risks typical of speculative biotech stocks. The company is developing a novel class of antiviral candidates based on its proprietary “nanoviricide” platform. These molecules are designed to mimic human cell surfaces, luring viruses to bind to them and thereby neutralizing the pathogens before they can infect real cells. If validated in human trials, this approach could represent a new method for treating infectious diseases. NanoViricides’ pipeline targets shingles (varicella-zoster virus), HSV-1 and HSV-2, and broad-spectrum influenza. Its shingles program, NV-HSC, is the most advanced and has shown encouraging preclinical antiviral activity. Like many micro-cap biotechs, NanoViricides remains pre-revenue and dependent on fresh capital to advance its programs. Recent filings show limited cash on hand, so investors should expect the possibility of future dilution. Still, if one candidate advances successfully into clinical development, the valuation upside could be substantial. For patient investors with a high tolerance for risk, NNVC represents a genuine moonshot in the antiviral space.
| 
